aTyr Pharma Statistics
Total Valuation
aTyr Pharma has a market cap or net worth of $108.06 million. The enterprise value is $21.51 million.
| Market Cap | 108.06M |
| Enterprise Value | 21.51M |
Important Dates
The next estimated earnings date is Tuesday, May 7, 2024, after market close.
| Earnings Date | May 7, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
aTyr Pharma has 67.75 million shares outstanding. The number of shares has increased by 88.63% in one year.
| Shares Outstanding | 67.75M |
| Shares Change (YoY) | +88.63% |
| Shares Change (QoQ) | +2.48% |
| Owned by Insiders (%) | 2.62% |
| Owned by Institutions (%) | 61.91% |
| Float | 60.12M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 306.12 |
| Forward PS | 49.50 |
| PB Ratio | 1.19 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 60.92 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.27, with a Debt / Equity ratio of 0.17.
| Current Ratio | 6.27 |
| Quick Ratio | 6.34 |
| Debt / Equity | 0.17 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -49.70% and return on invested capital (ROIC) is -51.93%.
| Return on Equity (ROE) | -49.70% |
| Return on Assets (ROA) | -39.10% |
| Return on Capital (ROIC) | -51.93% |
| Revenue Per Employee | $6,304 |
| Profits Per Employee | -$899,804 |
| Employee Count | 56 |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -22.20% in the last 52 weeks. The beta is 1.23, so aTyr Pharma's price volatility has been higher than the market average.
| Beta (1Y) | 1.23 |
| 52-Week Price Change | -22.20% |
| 50-Day Moving Average | 1.81 |
| 200-Day Moving Average | 1.62 |
| Relative Strength Index (RSI) | 36.53 |
| Average Volume (30 Days) | 556,808 |
Short Selling Information
The latest short interest is 383,052, so 0.57% of the outstanding shares have been sold short.
| Short Interest | 383,052 |
| Short Previous Month | 436,889 |
| Short % of Shares Out | 0.57% |
| Short % of Float | 0.64% |
| Short Ratio (days to cover) | 0.71 |
Income Statement
In the last 12 months, aTyr Pharma had revenue of $353,000 and -$50.39 million in losses. Loss per share was -$0.94.
| Revenue | 353,000 |
| Gross Profit | 353,000 |
| Operating Income | -54.92M |
| Pretax Income | -50.39M |
| Net Income | -50.39M |
| EBITDA | -47.65M |
| EBIT | -50.39M |
| Loss Per Share | -$0.94 |
Balance Sheet
The company has $101.65 million in cash and $15.10 million in debt, giving a net cash position of $86.56 million or $1.28 per share.
| Cash & Cash Equivalents | 101.65M |
| Total Debt | 15.10M |
| Net Cash | 86.56M |
| Net Cash Per Share | $1.28 |
| Equity / Book Value | 90.66M |
| Book Value Per Share | 1.34 |
| Working Capital | 86.58M |
Cash Flow
In the last 12 months, operating cash flow was -$33.22 million and capital expenditures -$4.20 million, giving a free cash flow of -$37.42 million.
| Operating Cash Flow | -33.22M |
| Capital Expenditures | -4.20M |
| Free Cash Flow | -37.42M |
| FCF Per Share | -$0.70 |
Margins
Gross margin is 100.00%, with operating and profit margins of -15,557.79% and -14,274.50%.
| Gross Margin | 100.00% |
| Operating Margin | -15,557.79% |
| Pretax Margin | -14,274.50% |
| Profit Margin | -14,274.50% |
| EBITDA Margin | -13,498.02% |
| EBIT Margin | -14,274.50% |
| FCF Margin | -10,600.85% |
Dividends & Yields
aTyr Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -88.63% |
| Shareholder Yield | -88.63% |
| Earnings Yield | -46.63% |
| FCF Yield | -34.63% |
Analyst Forecast
The average price target for aTyr Pharma is $23.67, which is 1,384.01% higher than the current price. The consensus rating is "Buy".
| Price Target | $23.67 |
| Price Target Difference | 1,384.01% |
| Analyst Consensus | Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (5Y) | 314.64% |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on July 1, 2019. It was a reverse split with a ratio of 1:14.
| Last Split Date | Jul 1, 2019 |
| Split Type | Reverse |
| Split Ratio | 1:14 |
Scores
aTyr Pharma has an Altman Z-Score of -3.8 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -3.8 |
| Piotroski F-Score | 2 |